TXNIP and diabetic retinopathy: Experimental models of diabetic retinopathy have shown that silencing thioredoxin interacting protein TXNIP prevents epigenetic modifications in the promoter of cyclooxygenase 2 (Cox2), an enzyme important in the synthesis of a major mediator of inflammation, prostaglandin E2 (PGE2) [91].